⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

THERANOSCAN : Biomarqueurs Théranostiques des Cancers Bronchiques Non à Petites Cellules

h-index: 30
Total citations: 3,869
Total papers: 225

Homepage: https://sante.sorbonne-universite.fr/structures-de-recherche/grc-4-theranoscan

Recent papers from THERANOSCAN : Biomarqueurs Théranostiques des Cancers Bronchiques Non à Petites Cellules

Small Molecules Prescribed On- and Off-Label for Thoracic Cancers During Pregnancy: A Combined VigiBase and Systematic Review AnalysisDrugs · 2026
Preclinical PET characterization of [68Ga]Ga-EMP-100 for non-invasive assessment of c-Met in NSCLCEJNMMI Research · 2026
A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinibFuture Oncology · 2026
Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 studyCancer Cell · 2026
Increased delays of care during the COVID-19 pandemic: experience of a lung cancer rapid diagnostic centerRespiratory Medicine and Research · 2025
Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV : Results from the ANRS CO4 French hospital database on HIVInternational Journal of Cancer · 2025
Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV : Results from the ANRS CO4 French hospital database on HIVInternational Journal of Cancer · 2025
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH studyAnnals of Oncology · 2025
Sacituzumab govitecan: a new hope for patients with pretreated extensive small-cell lung cancer (SCLC)—insights from the TROPiCS-03 trialTranslational Lung Cancer Research · 2025
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci studyEuropean Journal of Cancer · 2025
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort studyJournal for ImmunoTherapy of Cancer · 2024
Case 327: Exogenous Lipoid PneumoniaRadiology · 2024
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trialNature Medicine · 2024
High risk of lung cancer in surfactant-related gene variant carriersEuropean Respiratory Journal · 2024
Case 327Radiology · 2024
Fully automated radiolabeling of [68Ga]Ga-EMP100 targeting c-MET for PET-CT clinical imagingEJNMMI Radiopharmacy and Chemistry · 2023
Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case ReportsFrontiers in Oncology · 2023
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET FusionJournal of Thoracic Oncology · 2023
Sleep Traits, Night Shift Work and Lung Cancer Risk among Women: Results from a Population-Based Case-Control Study in France (The WELCA Study)International Journal of Environmental Research and Public Health · 2022
Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung CancerPharmaceutics · 2022